Artesunate protects against ischemic stroke through THBS2/CD36/TLR4 pathway
International Immunopharmacology · 2026-06 · 178 · 116562
DOI: 10.1016/j.intimp.2026.116562 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-06. Verfasst von Shanshan Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of …. Hauptthemen laut MEDLINE: Artesunate, Neuroprotective Agents, Ischemic Stroke, CD36 Antigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Natural Science Foundation of Anhui Province, Anhui Science and Technology Department, Anhui Province Department of Education.
Themen: Schlaganfall
Abstract (Originalsprache)
Stroke remains a major global health challenge, causing irreversible neuronal damage with limited therapeutic options. Artesunate (ART), a derivative of artemisinin, has shown anti-inflammatory and neuroprotective properties, but its mechanisms in protecting against ischemic stroke are not fully elucidated. This study investigated the potential mechanisms of ART in mitigating experimental ischemic stroke using a transient middle cerebral artery occlusion (tMCAO) mouse model and cellular oxygen-glucose deprivation/reperfusion (OGD/R) models. The results demonstrated that ART significantly reduced infarct volume, improved neurological and motor functions, and suppressed neuronal apoptosis, oxidative stress, and inflammation in the tMCAO model. Transcriptomic sequencing and subsequent validation suggested that ART exerts its effects by regulating Thrombospondin 2 (THBS2) expression, with molecular docking and cellular thermal shift assay (CETSA) indicating a high affinity between ART and THBS2. In vitro experiments confirmed that ART attenuated OGD/R-induced damage and inflammation, while overexpression of THBS2 reversed these protective effects. Further mechanistic analysis revealed that ART protects against ischemic injury by inhibiting the THBS2/CD36/TLR4 signaling pathway and THBS2 overexpression abolished ART-induced neuroprotection. In conclusion, ART exhibits significant neuroprotective effects in experimental ischemic stroke through the downregulation of the THBS2/CD36/TLR4 pathway, highlighting its potential as a therapeutic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China; Department of Anesthesiology, Anhui Provin…
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China. Electronic address: whuwangzhen1993@163.com.
Förderung
- Natural Science Foundation of Anhui Province
- Anhui Science and Technology Department
- Anhui Province Department of Education
Zitieren
APA
Luo, S., Zhang, Y., Li, B., Li, X., Wang, Y., Hu, C., Wu, C., Wu, Y., Wang, Z., & Tang, C. (2026). Artesunate protects against ischemic stroke through THBS2/CD36/TLR4 pathway. International Immunopharmacology, 178, 116562. https://doi.org/10.1016/j.intimp.2026.116562
Vancouver
Luo S, Zhang Y, Li B, Li X, Wang Y, Hu C, et al. Artesunate protects against ischemic stroke through THBS2/CD36/TLR4 pathway. International Immunopharmacology. 2026;178:116562. doi:10.1016/j.intimp.2026.116562
BibTeX
@article{Luo2026,
author = {Luo, Shanshan and Zhang, Yanhong and Li, Bilu and Li, Xingyu and Wang, Yongjiang and Hu, Chengyun and Wu, Chao and Wu, Yuyan and Wang, Zhen and Tang, Chaoliang},
title = {Artesunate protects against ischemic stroke through THBS2/CD36/TLR4 pathway},
journal = {International Immunopharmacology},
year = {2026},
volume = {178},
pages = {116562},
doi = {10.1016/j.intimp.2026.116562}
}
EUVIMED